What Is Coluracetam?
Coluracetam (originally coded MKC-231, later BCI-540) is a racetam-class compound and high-affinity choline uptake enhancer, sold as a research nootropic for memory and — anecdotally — visual effects. It was first investigated by Mitsubishi Tanabe for Alzheimer’s disease and later licensed for major depressive disorder, but development was discontinued. It is best understood as a research chemical: its mechanism is characterised mainly in animals, and there is essentially no published human efficacy evidence to support the popular claims made for it.
Evidence
The mechanistic and preclinical work is real: MKC-231/coluracetam was shown in rodents to enhance high-affinity choline uptake (the rate-limiting step in acetylcholine synthesis) and to reverse memory deficits and hippocampal acetylcholine depletion in AF64A-lesioned animals 1Reference 1AnimalMKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice — mouse studyView study →2Reference 2AnimalMKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats — rat studyView study →. That is the basis for its “choline uptake” reputation. However, this is animal data, and the human story is much thinner: the compound’s clinical development for cognition and for depression was discontinued, and I did not find a published, peer-reviewed human efficacy trial for coluracetam in this quick pass. The widely repeated claims about improved cognition, mood, and especially enhanced/vivid vision in humans are, as far as I could verify, based on animal work and user anecdote rather than any citable human trial — they should not be treated as established. Its toxicology, pharmacokinetics and long-term safety in humans are not well characterised.
Dosage & Safety
Because there is no established human dosing literature I can verify, no dosage range is given here; community dosing figures exist but are not backed by citable clinical trials, so stating one would imply an evidence base that does not exist. Coluracetam is a research chemical: it is not an approved medicine or dietary supplement, consumer-product purity is unverified, and its human safety profile is essentially uncharacterised (toxicity, drug interactions, and pregnancy safety are not established). This entry is informational only and is not a recommendation to use the compound.
References
- Murai S, Saito H, Masuda Y, et al. (1994). MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice — mouse study. Journal of Neural Transmission (General Section), 98(1):1–13. https://pubmed.ncbi.nlm.nih.gov/7710736/
- Takashina K, Bessho T, Mori R, et al. (2008). MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats — rat study. Journal of Neural Transmission, 115(7):1027–1035. https://pubmed.ncbi.nlm.nih.gov/18446264/